Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2018
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2018, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline landscape.
Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort to severe pain. Symptoms include decreased bladder capacity, painful sexual intercourse, chronic pelvic pain and a persistent, urgent need to urinate. Risk factors include age, gender and chronic pain disorder, such as irritable bowel syndrome or fibromyalgia. Treatment includes non-steroidal anti-inflammatory drug, antidepressants and antihistamines.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 3, 4, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2018, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline landscape.
Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort to severe pain. Symptoms include decreased bladder capacity, painful sexual intercourse, chronic pelvic pain and a persistent, urgent need to urinate. Risk factors include age, gender and chronic pain disorder, such as irritable bowel syndrome or fibromyalgia. Treatment includes non-steroidal anti-inflammatory drug, antidepressants and antihistamines.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 3, 4, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Interstitial Cystitis (Painful Bladder Syndrome) - Overview
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development
Aquinox Pharmaceuticals Inc
Astellas Pharma Inc
Idera Pharmaceuticals Inc
Kyorin Pharmaceutical Co Ltd
Kytogenics Pharmaceuticals Inc
Lipella Pharmaceuticals Inc
UCB SA
Urigen Pharmaceuticals Inc
Xigen SA
Interstitial Cystitis (Painful Bladder Syndrome) - Drug Profiles
(heparin sodium + lidocaine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit NLRP3 for Inflammation, Interstitial Cystitis and Uveitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-6294 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimapitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
certolizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyl sulfoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-16357 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICE-3682 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mesalamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rosiptor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
URG-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products
Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones
Featured News & Press Releases
Feb 09, 2018: Aquinox Provides Enrollment Update for LEADERSHIP 301 Clinical Trial of Rosiptor
Dec 15, 2017: Aquinox Promotes Lloyd Mackenzie to Chief Operating Officer and Vice President, R&D Operations
Dec 07, 2017: Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Nov 08, 2017: Aquinox Pharmaceuticals Announces Third Quarter 2017 Financial Results
Aug 28, 2017: Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome
Oct 03, 2016: Aquinox Announces Appointment of Dr. Barbara Troupin as Chief Medical Officer
Sep 27, 2016: Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society
Sep 06, 2016: Aquinox Pharmaceuticals Initiates Patient Dosing in LEADERSHIP 301 Phase 3 Clinical Trial of AQX-1125 in Interstitial Cystitis/Bladder Pain Syndrome
May 25, 2016: Aquinox Announces Executive Appointments
May 10, 2016: Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results
Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA
Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration
Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference
Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis
Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Interstitial Cystitis (Painful Bladder Syndrome) - Overview
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development
Aquinox Pharmaceuticals Inc
Astellas Pharma Inc
Idera Pharmaceuticals Inc
Kyorin Pharmaceutical Co Ltd
Kytogenics Pharmaceuticals Inc
Lipella Pharmaceuticals Inc
UCB SA
Urigen Pharmaceuticals Inc
Xigen SA
Interstitial Cystitis (Painful Bladder Syndrome) - Drug Profiles
(heparin sodium + lidocaine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit NLRP3 for Inflammation, Interstitial Cystitis and Uveitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-6294 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimapitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
certolizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyl sulfoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-16357 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICE-3682 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mesalamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rosiptor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
URG-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products
Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones
Featured News & Press Releases
Feb 09, 2018: Aquinox Provides Enrollment Update for LEADERSHIP 301 Clinical Trial of Rosiptor
Dec 15, 2017: Aquinox Promotes Lloyd Mackenzie to Chief Operating Officer and Vice President, R&D Operations
Dec 07, 2017: Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Nov 08, 2017: Aquinox Pharmaceuticals Announces Third Quarter 2017 Financial Results
Aug 28, 2017: Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome
Oct 03, 2016: Aquinox Announces Appointment of Dr. Barbara Troupin as Chief Medical Officer
Sep 27, 2016: Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society
Sep 06, 2016: Aquinox Pharmaceuticals Initiates Patient Dosing in LEADERSHIP 301 Phase 3 Clinical Trial of AQX-1125 in Interstitial Cystitis/Bladder Pain Syndrome
May 25, 2016: Aquinox Announces Executive Appointments
May 10, 2016: Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results
Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA
Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration
Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference
Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis
Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Astellas Pharma Inc, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Idera Pharmaceuticals Inc, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals Inc, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals Inc, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UCB SA, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals Inc, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Xigen SA, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H1 2018
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Astellas Pharma Inc, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Idera Pharmaceuticals Inc, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals Inc, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals Inc, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UCB SA, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals Inc, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Xigen SA, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H1 2018
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Aquinox Pharmaceuticals Inc
Astellas Pharma Inc
Idera Pharmaceuticals Inc
Kyorin Pharmaceutical Co Ltd
Kytogenics Pharmaceuticals Inc
Lipella Pharmaceuticals Inc
UCB SA
Urigen Pharmaceuticals Inc
Xigen SA
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Aquinox Pharmaceuticals Inc
Astellas Pharma Inc
Idera Pharmaceuticals Inc
Kyorin Pharmaceutical Co Ltd
Kytogenics Pharmaceuticals Inc
Lipella Pharmaceuticals Inc
UCB SA
Urigen Pharmaceuticals Inc
Xigen SA
